Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.24
Oct 30 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
3.73M
Enterprise Value
12.95M
Income
-33.49M
Sales
7.69M
Book/sh
2.69
Cash/sh
9.14
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
54
IPO
Sep 23, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
0.49
P/B
0.83
P/C
0.25
P/FCF
-
EV/EBITDA
-
EV/Sales
1.68
Quick Ratio
3.12
Current Ratio
3.31
Debt/Eq
11.80
LT Debt/Eq
11.57
Option/Short
No / Yes
EPS (ttm)
-68.49
EPS next Y
-
EPS next Q
-3.31
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
52.44% 30.89%
Sales past 3/5Y
- 54.47%
EPS Y/Y TTM
71.34%
Sales Y/Y TTM
60.75%
EPS Q/Q
64.13%
Sales Q/Q
0.45%
Insider Own
15.03%
Insider Trans
32.97%
Inst Own
4.71%
Inst Trans
2.67%
ROA
-109.80%
ROE
-561.77%
ROIC
-133.22%
Gross Margin
4.18%
Oper. Margin
-364.76%
Profit Margin
-435.71%
SMA20
-2.13%
SMA50
-26.25%
SMA200
-78.61%
Trades
Shs Outstand
1.67M
Shs Float
1.42M
52W High
53.20 -95.79%
52W Low
2.05 9.27%
Volatility
6.54% 7.97%
ATR (14)
0.21
RSI (14)
39.70
Beta
0.22
Rel Volume
0.00
Avg Volume
220.18K
Volume
0
Perf Week
7.18%
Perf Month
-23.55%
Perf Quarter
-64.61%
Perf Half Y
-78.21%
Perf YTD
-84.57%
Perf Year
-94.40%
Perf 3Y
-99.75%
Perf 5Y
-99.95%
Perf 10Y
-99.98%
Prev Close
2.24
Price
2.24
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$18.33
Implied Upside
+718.3%
Analysts6incl. previous ratings
Rating Distribution5 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 01, 2026Initiated
LLake Street
Buy$10+346.4%
Jul 17, 2025Initiated
DD. Boral Capital
Buy$11+391.1%
Jun 25, 2024Downgrade
BBTIG Research
Buy → Neutral
Jul 28, 2023Initiated
PPiper Sandler
Overweight$10+346.4%
Jun 15, 2023Initiated
BBTIG Research
Buy$15+569.6%
Apr 28, 2021Initiated
TFC logoTTruist
Buy$12+435.7%
Oct 22, 2019Initiated
OPY logoOOppenheimer
Outperform$9+301.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lin Yi-Chien10% OwnerOct 13 '26Buy2.212,6075,761148,000Oct 14 12:14 PM
Lin Yi-Chien10% OwnerOct 01 '26Buy2.8015,39343,100145,393Oct 02 08:24 PM
Lin Yi-Chien10% OwnerSep 29 '26Buy2.693,0008,070128,000Oct 02 08:24 PM
Lin Yi-Chien10% OwnerSep 30 '26Buy2.712,0005,420130,000Oct 02 08:24 PM
Goodman Robert ScottChief Executive OfficerJul 29 '26Buy5.7634,722199,99934,822Jul 31 06:55 PM
MOORHEAD DANIEL JChief Financial OfficerJul 29 '26Buy5.764,34024,9984,340Jul 31 06:21 PM
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air, Beyond Cancer segments, and NeuroNos. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.
CEO & DirectorMr. Robert Scott Goodman
Chief Financial OfficerMr. Daniel J. Moorhead CPA
Chief Operating OfficerMr. Michael A. Gaul
Principal Accounting Officer & ControllerMr. Denton Drewell
Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory BoardDr. Andrew R. Colin M.D.